TROUBLE VIEWING? Click Here to view the Promo card on the web
SIGN-UP NOW! Click to become a Member for Free!
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

October 31st 2017: Research Update From Summit Therapeutics on Ridinilazole

Join Us With Guest Dr. Richard Vickers, Ph.D., Chief Scientific Officer at Summit Therapeutics joining us to discuss their research on a new antibiotic to treat a C. difficile infection. Learn more about Ridinilazole, clinical trials and the progress being made and moving closer to getting an urgently needed new treatment available for CDI to patients.

Download PDF DOWNLOAD PDF

Tune in
Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live! Call-In
Toll Free:  1-866-472-5792
Intl:  001-480-553-5759

Featured Guest
Guest Image

Richard Vickers Ph.D.
Dr. Vickers is Chief Scientific Officer, Antimicrobials and Programme Lead for CDI, Summit Therapeutics. He joined Summit in 2003 and during his time has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs.
Read more

Share This Episode
facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn

Connect with VoiceAmerica
Download our mobile apps
App store Google play Blackberry store
Facebook Twitter Linkedin Social Media
presspass-banner